Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease
The long-term clinical outcomes and associated prognostic factors in contactin-associated protein-like 2 (CASPR2)-antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality-of-life, and chronic pain. Although most symptoms im...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2025
|
| _version_ | 1824459100066414592 |
|---|---|
| author | Ceronie, B Strippel, C Uy, C Paneva, S Makuch, M Soleimani, B Turaga, S Binks, S Ramanathan, S Michael, S Varley, J Easton, A Themistocleous, A John Dawes Bennett, DL Irani, A Handel, AE Irani, SR |
| author_facet | Ceronie, B Strippel, C Uy, C Paneva, S Makuch, M Soleimani, B Turaga, S Binks, S Ramanathan, S Michael, S Varley, J Easton, A Themistocleous, A John Dawes Bennett, DL Irani, A Handel, AE Irani, SR |
| author_sort | Ceronie, B |
| collection | OXFORD |
| description | The long-term clinical outcomes and associated prognostic factors in contactin-associated protein-like 2 (CASPR2)-antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality-of-life, and chronic pain. Although most symptoms improved within 6 months of treatment, neuropathic pain and fatigue were the most immunotherapy refractory, and persisted for up to 6 years. Furthermore, these two factors—but not CASPR2 antibody levels or subclasses—independently predicted worse disability and quality-of-life at 24 months. Quality-of-life varied widely for any given modified Rankin Scale score, indicating a divergence between patient and clinician assessed outcomes. Further work should study the relative importance of these measures, and the immunopathogenesis underlying intractable symptoms. ANN NEUROL 2025 |
| first_indexed | 2025-02-19T04:36:25Z |
| format | Journal article |
| id | oxford-uuid:79af27ab-3788-410b-a9cd-797dd039f33d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:36:25Z |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:79af27ab-3788-410b-a9cd-797dd039f33d2025-01-31T09:13:54ZImmunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:79af27ab-3788-410b-a9cd-797dd039f33dEnglishSymplectic ElementsWiley2025Ceronie, BStrippel, CUy, CPaneva, SMakuch, MSoleimani, BTuraga, SBinks, SRamanathan, SMichael, SVarley, JEaston, AThemistocleous, AJohn DawesBennett, DLIrani, AHandel, AEIrani, SRThe long-term clinical outcomes and associated prognostic factors in contactin-associated protein-like 2 (CASPR2)-antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality-of-life, and chronic pain. Although most symptoms improved within 6 months of treatment, neuropathic pain and fatigue were the most immunotherapy refractory, and persisted for up to 6 years. Furthermore, these two factors—but not CASPR2 antibody levels or subclasses—independently predicted worse disability and quality-of-life at 24 months. Quality-of-life varied widely for any given modified Rankin Scale score, indicating a divergence between patient and clinician assessed outcomes. Further work should study the relative importance of these measures, and the immunopathogenesis underlying intractable symptoms. ANN NEUROL 2025 |
| spellingShingle | Ceronie, B Strippel, C Uy, C Paneva, S Makuch, M Soleimani, B Turaga, S Binks, S Ramanathan, S Michael, S Varley, J Easton, A Themistocleous, A John Dawes Bennett, DL Irani, A Handel, AE Irani, SR Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title | Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title_full | Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title_fullStr | Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title_full_unstemmed | Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title_short | Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease |
| title_sort | immunotherapy resistant neuropathic pain and fatigue predict quality of life in contactin associated protein like 2 antibody disease |
| work_keys_str_mv | AT ceronieb immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT strippelc immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT uyc immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT panevas immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT makuchm immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT soleimanib immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT turagas immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT binkss immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT ramanathans immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT michaels immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT varleyj immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT eastona immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT themistocleousa immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT johndawes immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT bennettdl immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT irania immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT handelae immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease AT iranisr immunotherapyresistantneuropathicpainandfatiguepredictqualityoflifeincontactinassociatedproteinlike2antibodydisease |